{"id":21605,"date":"2024-07-01T15:54:30","date_gmt":"2024-07-01T15:54:30","guid":{"rendered":"https:\/\/clinlabint.com\/?p=21605"},"modified":"2024-07-02T12:45:49","modified_gmt":"2024-07-02T12:45:49","slug":"strategic-partnership-to-advance-monoclonal-antibody-discovery","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/strategic-partnership-to-advance-monoclonal-antibody-discovery\/","title":{"rendered":"Strategic partnership to advance monoclonal antibody discovery"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Strategic partnership to advance monoclonal antibody discovery<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Icosagen, a contract research, development, and manufacturing organisation (CRDMO) specialising in innovative antibody research and production, has announced a strategic partnership with Lead Discovery Center GmbH (LDC), a translational drug discovery organisation. The collaboration aims to discover monoclonal antibody portfolios targeting therapeutically relevant proteins, including a pivotal G-protein coupled receptor (GPCR), which are often challenging to address.<\/h3>\n

<\/p>\n

Scope of collaboration<\/h4>\n

The partnership will leverage Icosagen\u2019s proprietary technology to produce proteins of interest and enhance their display on virus-like particles. These particles will serve as vehicles for the production of high-affinity antibodies. Icosagen will then establish an extensive library to facilitate the selection of high-affinity monoclonal antibodies, which will undergo further analysis at LDC through a streamlined high-throughput screening process.<\/p>\n

Professor Mart Ustav, CEO of Icosagen, commented: \u201cPartnering with LDC will further help expand the opportunities for antibody therapeutics, especially in the challenging field of GPCR-targeted<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

treatments. This will not only highlight our technological expertise but also perfectly aligns with our mission to transform scientific discoveries into life-changing treatments.\u201d<\/p>\n

Dr Bert Klebl, CEO and CSO of LDC, added: \u201cWe are excited to partner up with Icosagen, a competent and highly experienced player in the field of antibody research. This project will greatly benefit from Icosagen\u2019s expertise and state-of-the-art capabilities as we pursue our shared goal: the development of novel therapeutics that can make a\u00a0 meaningful difference in healthcare.\u201d<\/p>\n

Future prospects<\/h4>\n

The collaboration between Icosagen and LDC is expected to advance the development of targeted therapeutics, potentially revolutionising treatment approaches for various diseases. LDC\u2019s role in transforming early-stage academic projects into innovative pharmaceutical leads and antibodies, coupled with Icosagen\u2019s expertise in antibody discovery, presents a promising outlook for the development of novel therapeutics with significant medical and commercial potential.<\/p>\n<\/div><\/section>
\n